Mitochondrial Diseases Clinical Trial
— NuPowerOfficial title:
A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower
Verified date | December 2023 |
Source | Stealth BioTherapeutics Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).
Status | Active, not recruiting |
Enrollment | 102 |
Est. completion date | October 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: A subject must meet all of the following inclusion criteria at the Screening and Baseline Visit (unless otherwise specified) to be eligible for inclusion in the SPIMD-301 trial: 1. Willing and able to provide a signed informed consent form (ICF) prior to participation in any trial-related procedures. 2. Agrees and is able to adhere to the trial requirements for the length of the trial, including administration of assigned treatment. 3. Is =18 years and = 70 years of age at the time of screening. 4. Diagnosed with nPMD with a predominant clinical manifestation of myopathy, which must include progressive external ophthalmoplegia (PEO) and exercise intolerance and/or skeletal muscle weakness, with genetic confirmation of either: 1. Nuclear DNA mutation of the mitochondrial replisome (replisome-related mutations), which include the following genes: - POLG 1/2 - TWINKLE (C10ORF2) - TYMP - DGUOK - TK2 - RRM2B - RNASEH1 - SSBP - MGME1 - DNA2 - ANT1 (SLC25A4) - SUCLG1 - SUCLA2 - MPV17 or 2. Other pathogenic mutations specific to nuclear DNA. 5. Women of childbearing potential must agree to use one of the following methods of birth control from the date they sign the ICF until 28 days after the last dose of IMP: 1. Abstinence, when it is in line with the preferred and usual lifestyle of the subject. Subject agrees to use a highly effective method of contraception should they become sexually active. 2. Relationships with male partners who have been surgically sterilized by vasectomy (the vasectomy procedure must have been conducted at least 60 days prior to the Screening Visit). 3. Barrier method (e.g., condom or occlusive cap) with spermicidal foam/gel/film/cream AND either hormonal contraception (oral, implanted, or injectable) or an intrauterine device or system. Note: Non-childbearing potential is defined as surgical sterilization (e.g., bilateral oophorectomy, hysterectomy, or tubal ligation) or postmenopausal (defined as permanent cessation of menstruation for at least 12 consecutive months prior to the Screening Visit). 6. Male subjects with female partners of childbearing potential must be willing to use a highly effective method of contraception from the date they sign the ICF until 28 days after the last dose of IMP. Exclusion Criteria: 1. Is unable to perform the 6MWT, 3TUG, or 5XSST functional tests. The use of a gait assist device is allowed; however, use should remain consistent for the entire duration of the trial. 2. Female subjects who are pregnant, planning to become pregnant, or breastfeeding/lactating. 3. Walks < 150 meters or > 450 meters during the 6MWT (Screening Visit only). 4. The estimated glomerular filtration rate (eGFR) is < 30 mL/min/1.73 m2, using the Modification of Diet in Renal Disease (MDRD) Study equation (Screening Visit only). 5. Has undergone an in-patient hospitalization within 30 days prior to screening or has a planned hospitalization or a surgical procedure during the trial, unless, in the opinion of the Investigator, it is concluded that it will not impact the outcome measurements of the trial. 6. Has clinically significant respiratory disease and/or cardiac disease that would interfere with trial assessments, in the opinion of the Investigator. 7. Has had any prior interventional cardiac procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention, balloon valvuloplasty, etc.) within 3 months prior to screening. 8. Has history of or current severe neurologic impairment, severe epilepsy, severe ataxia, or severe neuropathy that may interfere with their ability to complete all trial requirements, in the opinion of the Investigator. 9. Active malignancy or any other cancer from which the subject has been disease-free for < 2 years. Localized squamous or non-invasive basal cell skin carcinomas are allowed, if appropriately treated prior to screening. 10. Has had a solid organ transplant. 11. Has been previously diagnosed with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection. 12. Has a history of a systemic eosinophilic illness and/or an eosinophil count >1,000 cells x106/L at the Screening Visit. 13. Is currently participating or has participated in an interventional clinical trial (i.e., investigational product or device, stem cell therapy, gene therapy) within 30 days prior to current trial; or is currently enrolled in a non-interventional clinical trial that, in the opinion of the Investigator, may be potentially confounding to the results of the current trial (e.g., exercise therapy trial). 14. Has received elamipretide (MTP-131) within the past one year of the Screening Visit. 15. Has a history of active substance abuse during the year prior, in the opinion of the Investigator. |
Country | Name | City | State |
---|---|---|---|
Australia | Calvary Health Care Bethlehem | Parkdale | Victoria |
Australia | Royal North Shore Hospital Neurology | Sydney | New South Wales |
Germany | Universitaetsklinikum Carl Gustav Carus Dresden Neurologie | Dresden | |
Germany | Department of Neurology, University Clinics Munich | Munich | Bavaria |
Germany | Univ of Tubingen, Hertie Institute for Clinical Brain Research | Tübingen | |
Hungary | Semmelweis Egyetem Genomikai Medicina es Ritka Betegsegek | Budapest | |
Hungary | University of Pécs, Department of Neurology Klinikai Kozpont - neurologiai Klinika | Pecs | |
Italy | IRCCS Institute of Neorological Sciences of Bologna Bellaria Hospital | Bologna | |
Italy | University of Brescia, NeMO Clinical Center for Neuromuscular Diseases | Gussago | Brescia |
Italy | Azienda Ospedaliero Universitaria Policlinico G. Martino | Messina | |
Italy | Istituto Nazionale Neurologico Carlo Besta | Milano | |
Italy | Azienda Ospedaliero Universitario Pisana, Dipartimento Ambientale di Neuroscienze | Pisa | |
Italy | Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore | Roma | Lazio |
Netherlands | Radboud University Medical Center | Nijmegen | |
New Zealand | University of Auckland - Auckland City Hospital, Neurology Department | Auckland | |
Norway | Helse Bergen HF | Bergen | |
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital de la Sta Creu i Sant Pau | Barcelona | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital la Fe de Valencia | Valencia | |
United Kingdom | University of Cambridge, Department of Clinical Neurosciences | Cambridge | |
United Kingdom | Queen Square Centre for Neuromuscular Diseases The National Hospital for Neurology and Neurosurgery | London | |
United Kingdom | Newcastle upon Tyne Hospitals Freeman Hospital | Newcastle | |
United States | Akron Children's Hospital | Akron | Ohio |
United States | Rare Disease Research, LLC | Atlanta | Georgia |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | UT Health,Center for the Treatment of Pediatric Neurodegenerative Disease | Houston | Texas |
United States | Columbia University Medical Center College of Physician and Surgeon | New York | New York |
United States | The Children's Hospital of Philadelphia | Philadelphia | Pennsylvania |
United States | University of Pittsburgh School of Medicine Children's Hospital of Pittsburgh of UPMC Department of Genetics | Pittsburgh | Pennsylvania |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | University of California, San Diego | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Stealth BioTherapeutics Inc. |
United States, Australia, Germany, Hungary, Italy, Netherlands, New Zealand, Norway, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Six-minute walk test (6MWT) | Change from Baseline in Distance Walked (in meters) on the Six-Minute Walk Test by Visit | Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit) | |
Secondary | 5 times sit-to-stand test (5XSST) | Change from Baseline in Total time (in seconds) to complete the 5XSST. Participant is directed to stand up straight as quickly as possible 5 times, without stopping in between, keeping arms folded across the chest. An average time is calculated. | Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit) | |
Secondary | Triple Timed up-and-go test (3TUG) | Change from Baseline in Total time (in seconds) to complete the 3TUG. Participant is directed to stand up from chair, walk at normal pace to the line on the floor 3 meters away, turn, walk back to the chair at normal pace, sit down again; activity is timed, in seconds. Activity is repeated 3 times consecutively without rest and an average time is calculated. | Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit) | |
Secondary | Patient Global Impression of Severity (PGI-S) Scale | Change from Baseline for PGI of Severity (PGI-S) Scale. Patient-reported current health status by week and at end of treatment. PGI-S Scale is a categorical scale and asks the participant to "rate the severity of your muscle weakness symptoms today" as one of the following categories: None, Mild, Moderate, Severe, or Very Severe. None means better health status, and best outcome, Very severe means worse health status and worse outcome. | Baseline, Weeks 12, 24, 36, 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03388528 -
Low Residue Diet Study in Mitochondrial Disease
|
N/A | |
Completed |
NCT04378075 -
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
|
Phase 2/Phase 3 | |
Completed |
NCT03678740 -
Diagnostic Odyssey Survey 2
|
||
Recruiting |
NCT06051448 -
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
|
Phase 1/Phase 2 | |
Completed |
NCT02909400 -
The KHENERGY Study
|
Phase 2 | |
Completed |
NCT02398201 -
A Study of Bezafibrate in Mitochondrial Myopathy
|
Phase 2 | |
Completed |
NCT03857880 -
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip
|
||
Not yet recruiting |
NCT06450964 -
Establishment of Reproductive Cohort and Prediction Model of Genetic Counseling for Mitochondrial Genetic Diseases
|
||
Completed |
NCT04165239 -
The KHENERGYZE Study
|
Phase 2 | |
Completed |
NCT02284334 -
Glycemic Index in Mitochondrial Disease
|
||
Recruiting |
NCT06080568 -
Human Mitochondrial Stress-driven Obesity Resistance
|
||
Recruiting |
NCT06080581 -
Mitochondrial Dysfunctions Driving Insulin Resistance
|
||
Recruiting |
NCT04802707 -
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
|
Phase 2 | |
Completed |
NCT04594590 -
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy
|
||
Completed |
NCT04580979 -
Natural History Study of FDXR Mutation-related Mitochondriopathy
|
||
Withdrawn |
NCT03866954 -
Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy
|
Phase 2 | |
Recruiting |
NCT04113447 -
Mitochondrial Donation: An 18 Month Outcome Study.
|
||
Enrolling by invitation |
NCT04734626 -
CrCest Study in Primary Mitochondrial Disease
|
||
Completed |
NCT03832218 -
Executive Function Disorders and Anxio-depressive Symptomatology in Children and Adolescents With Mitochondrial Pathologies
|
N/A | |
Terminated |
NCT02473445 -
A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease
|
Phase 2 |